Immunological efficacy of Jinhua Qinggan Granule for COVID-19
Not Applicable
Completed
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000040407
- Lead Sponsor
- Administration Department, Takanawa Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
Current infectious, inflammatory, or immune-related diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma cytokine levels 1 hour after the administration of JHQG
- Secondary Outcome Measures
Name Time Method Hematology and blood biochemistry 1 hour after the administration of JHQG
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which Jinhua Qinggan Granule modulates immune responses in COVID-19 patients?
How does the immunological efficacy of Jinhua Qinggan Granule compare to standard-of-care treatments for mild to moderate SARS-CoV-2 infections?
Are there specific biomarkers that correlate with improved clinical outcomes in patients treated with Jinhua Qinggan Granule for viral pneumonia caused by SARS-CoV-2?
What are the potential adverse events associated with Jinhua Qinggan Granule therapy in the context of acute respiratory distress syndrome (ARDS) from SARS-CoV-2 infection?
What is the therapeutic potential of Jinhua Qinggan Granule in combination with antiviral agents like remdesivir for SARS-CoV-2-induced cytokine storm syndromes?